Akeso Therapeutics Inc

Yorktown Heights, NY · Biotech · Public

CD7 CAR-modified allogeneic invariant Natural Killer T (iNKT) cell therapeutic for T-cell malignancies

Grants
$398K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
4
0 granted · 4 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Chimeric antigen receptor-modified iNKT cell therapy for CD7+ malignancies$398,040
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1929Surf Air Global Ltd—$9.9M
1930GENOMEDESIGNS LABORATORY, LLC——
1931Prologue Medicines——
1932Akeso Therapeutics Inc——
1933XEME Biopharma, Inc.—$10M
1934Boston Mountain Biotech, LLC—$8.4M
1935ANGIOTENSIN THERAPEUTICS, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 4
  • Type III Nkt Cells And Related Compositions And Methodsapplication
  • Modified Invariant Natural Killer T Cells Expressing Chimeric Antigen Receptor And Uses Thereofapplication
  • Type III Nkt Cells And Related Compositions And Methodsapplication
  • Type II Nkt Cells And Related Compositions And Methodsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.